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Background: The combination of carboplatin and docetaxel has
been considered one of the standard treatments for advanced non-
small cell lung cancer (NSCLC). To investigate a safer and more
convenient schedule for outpatient, we conducted a phase II study to
evaluate the efficacy and the safety of carboplatin plus biweekly
docetaxel for advanced NSCLC.
Patients and Methods: Patients with stage IIIB, IV, or postopera-
tive recurrent NSCLC with good performance status were adminis-
tered docetaxel at a dose of 35 mg/m2 on days 1 and 15 and
carboplatin at an area under the curve (AUC) of 6 on day 1 every 4
weeks for at least three cycles.
Results: Fifty patients were treated with median of three cycles
(range 1–6). Grade 3/4 toxicities included neutropenia in 18 patients
(36%), thrombocytopenia in 4 patients (8%), and anemia in 10
patients (20%). No patient experienced febrile neutropenia. Nonhe-
matological toxicities were also mild to moderate, and there were no
treatment-related deaths. The overall response rate was 30%, and the
disease control rate was 70%. Among the elderly population, 54% of
patients achieved partial response. Median progression-free survival
was 4.8 months, and median overall survival was 11.8 months.
Conclusions: Biweekly docetaxel plus carboplatin has a similar
efficacy and lower toxicity compared with a standard triweekly
regimen of docetaxel plus carboplatin, which is a suitable regimen
for outpatients, including elderly patients.
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Lung cancer is the leading cause of cancer-related deaths inJapan and throughout the Western world.1 Although che-
motherapy for metastatic non-small cell lung cancer (NSCLC)
had been considered ineffective and toxic, a meta-analysis of
randomized controlled trials has shown that chemotherapy
containing cisplatin improved the 1-year survival rate by 10%
and prolonged median survival by 1.5 months compared with
best supportive care.2 Since new drugs including taxanes,
gemcitabine, and vinorelbine have become available, the
combination of one of these agents and a platinum compound
has been considered the standard chemotherapy regimen for
metastatic NSCLC.3
One of these platinum compounds, cisplatin, requires
hydration to prevent renal damage and is therefore not indi-
cated in the treatment of outpatients. To alleviate the renal
toxicity of cisplatin, carboplatin was developed as a second-
generation platinum compound. In NSCLC, the antitumor
effect of carboplatin was found to be almost equal to that of
cisplatin,4 although meta-analyses suggested that cisplatin
was slightly superior to carboplatin, at least in terms of
response.5,6 Because carboplatin does not induce renal
damage or emesis, it is suitable for outpatient-based che-
motherapy.
Carboplatin and docetaxel have different mechanisms
of antitumor action, and most of their toxicities do not
overlap. In addition, because docetaxel and platinum com-
pounds do not have cross-tolerance, their combination may
have higher efficacy than either alone. A randomized phase
III study showed no difference in efficacy between docetaxel/
carboplatin and cisplatin/vinorelbine.7 Other studies have
reported that docetaxel plus carboplatin had response rates of
39 and 43% and tolerable toxicity.8,9
When given at a dose of 60 to 70 mg/m2, docetaxel is
usually administered at intervals of 3 to 4 weeks. In contrast,
weekly administration of docetaxel, divided into doses of 25
to 40 mg/m2 for 3 to 6 weeks, had less hematological
toxicity,10,11 but docetaxel-induced pneumonitis was more
frequent.12 Biweekly administration of docetaxel is an attrac-
tive alternative because it seems to be safe, effective, and
convenient for outpatient-based chemotherapy. As a result of
our previous phase I study, docetaxel at a dose of 35 mg/m2
on days 1 and 15 with carboplatin at an area under the curve
(AUC) of 6 on day 1 were recommended for the phase II
trial.13 We therefore designed this phase II trial of biweekly
docetaxel combined with carboplatin for patients with ad-
vanced NSCLC.
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PATIENTS AND METHODS
Patient Eligibility
The study population consisted of untreated patients
older than 20 years of age with cytologically or histologically
confirmed NSCLC of stage IIIB with pleural effusion, stage
IV, or postoperative recurrence with distant metastasis. Other
eligibility criteria included an Eastern Cooperative Oncology
Group performance status (PS) of 0 or 1 and a life expectancy
of more than 3 months. Laboratory requirements included
hemoglobin 9 g/dl, white blood cell count 4000/mm3,
neutrophils 2000/mm3, platelets 100,000/mm3, total bil-
irubin 1.5 mg/dl, transaminase 1.5 times the institutional
upper limit of the normal value, serum creatinine1.5 mg/dl,
and PaO2 60 mm Hg. Patients were ineligible if they had
symptomatic brain metastases, active double cancer, or a
severe comorbidity contraindicating chemotherapy, such as
symptomatic cardiovascular disease, uncontrolled diabetes,
pulmonary fibrosis obvious in a chest x-ray, or a severe
infectious disease. An institutional review board of each
hospital approved this study, and written informed consent
was obtained from each patient.
Drug Administration and Modification
During each 28-day cycle, docetaxel (35 mg/m2) was
administered intravenously on days 1 and 15, with intrave-
nous carboplatin (AUC 6) administered immediately after-
ward on day 1. The carboplatin dose was calculated using the
Calvert formula, with creatinine clearance estimated by the
Cockroft–Gault equation. Before administration of anticancer
agents, each patient received antiemetic agents consisting of
8 mg of dexamethasone and a 5-HT3 antagonist intrave-
nously. No prophylactic granulocyte colony–stimulating fac-
tor or prophylactic antibiotic support was planned.
Toxicities were assessed according to the National
Cancer Institute Common Toxicity Criteria version 2.0. Do-
cetaxel on day 15 was administered when the neutrophil
count was more than 1000/mm3 and the platelet count was
more than 75,000/mm3. Dose reduction in subsequent cycles
was permitted in cases of carboplatin reduced to AUC 5 with
grade 4 neutropenia lasting 4 days, febrile neutropenia
1000/mm3, thrombocytopenia 20,000/mm3 or the need
for platelet transfusion, or if a major nonhematological tox-
icity of at least grade 3, excluding anorexia or nausea. If such
toxicities were still observed, the docetaxel dose was reduced
to 30 mg/m2 in the next cycle.
It was intended that all patients would receive at least
three cycles unless their disease progressed, unacceptable
toxicity occurred, the patient refused further treatment, or the
physician decided to discontinue the treatment. Second-line
chemotherapy or other treatments after this study were not
restricted by the protocol.
Treatment Assessment
Baseline assessment included a physical examination,
complete blood cell counts, hepatic and renal function tests,
urinalysis, 12-lead electrocardiograph, and chest x-ray. Mea-
surements of visible and palpable tumors were performed at
baseline by chest x-ray, computed tomography scans, or
magnetic resonance imaging scans. During the study, the
medical history and results of physical examination, weight,
vital signs, Eastern Cooperative Oncology Group PS, com-
plete blood cell counts, and blood chemistry were monitored
weekly, and urinalysis was performed every 3 weeks. Radio-
graphic evaluation by computed tomography was performed
to assess each patient’s response to the treatment. Unidirec-
tional measurements were undertaken using the new World
Health Organization criteria (RECIST criteria).14 Complete
response (CR) was defined as the disappearance of all lesions,
partial response (PR) was defined as a decrease of at least
30% in the sum of the longest diameter of the tumor,
progressive disease (PD) was defined as an increase of at least
20% of the longest diameter of the tumor or the appearance of
any new lesions, and stable disease was defined as any
response other than CR, PR, or PD. Tumor response assess-
ment was performed after every chemotherapy cycle.
Study Design and Statistical Analysis of the
Phase II Trial
The primary objective of the trial was to determine
response rate, defined as the proportion of the patients who
attained CR or PR. Simon’s two-stage optimal design15 was
used to determine the sample size and interim decision
criteria. Assuming that a response rate of 40% in eligible
patients would indicate potential usefulness, whereas a rate of
20% would be the lower limit of interest, with alpha  0.05
TABLE 1. Patient Characteristics
No. of
Patients
Enrolled patients 50
Sex (male/female) 42/8
Median age (yr) 65
Age range (yr) 34–79
Performance status* (0/1/2) 21/28/1**
Histology
Adenocarcinoma 30
Squamous cell carcinoma 11
Large cell carcinoma 9
Stage
IIIB 8
IV 36
Postoperative recurrence 6
*Eastern Cooperative Oncology Group performance status; **ineligible case.
TABLE 2. Response Rate
Response No. of Patients (%)
Complete response 0 (0)
Partial response 15 (30)
Stable disease 20 (40)
Progressive disease 15 (30)
Not evaluable 0 (0)
Overall response 15 (30)
95% confidence interval (%) 17.3–42.7
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and beta 0.10, 45 patients would be required. This regimen
would be rejected when only 5 of the first 24 patients had an
objective response at the interim analysis or when 13 of 45
patients had an objective response at final analysis. The
secondary endpoint was toxicity and overall survival. Overall
survival was defined as the interval between the start of
treatment and the date of death or the last follow-up visit.
Survival distribution was estimated by the Kaplan–Meier
method.
RESULTS
Patient Characteristics
From October 2003 to February 2005, 50 NSCLC
patients were enrolled from seven participating institutions.
Patient characteristics are summarized in Table 1. More than
half of enrolled patients had PS 1 (there was one case with PS
2), and 13 patients (26%) were elderly (70 years old). The
predominant histology was adenocarcinoma (60%). Eight
patients (16%) were stage IIIB, and six (12%) had postoper-
ative recurrence with distant metastasis.
Tumor Response and Survival
Fifty patients received a total of 132 cycles of the
protocol treatment; the median number of cycles was three
(range, 1–6). All patients could be evaluated for response
(Table 2). The overall response rate was 30% (95% confi-
dence interval [CI] 17.3–42.7%). Stable disease was ob-
served in 20 patients (40%), and PD was observed in 15
patients (30%). Among the 13 elderly patients, 7 (54%; 95%
CI, 26.7–81.0%) experienced PR, whereas PR observed in
younger patients was 8 (22%; 95% CI, 8.4–34.9%).
Survival analysis was performed in September 2005.
The median follow-up for the living patients was 10.9 months
TABLE 3. Toxicities
Grade
0 1 2 3 4 Grade 3/4
No. No. No. No. No. No. (%)
Hematologic
Neutropenia 15 5 11 11 8 19 (38)
Febrile neutropenia 50 0 0 0 0 0 (0)
Anemia 5 19 16 9 1 10 (20)
Thrombocytopenia 21 16 8 4 1 5 (10)
Nonhematologic
Anorexia 13 23 12 1 1 2 (4)
Nausea/vomiting 27 13 10 0 0 0 (0)
Fatigue 42 5 3 0 0 0 (0)
Diarrhea 46 4 0 0 0 0 (0)
Infection 48 0 2 0 0 0 (0)
Hiccoughs 45 5 0 0 0 0 (0)
Fever 36 9 5 0 0 0 (0)
Injection-site reaction 47 1 2 0 0 0 (0)
Alopecia 26 18 6 0 0 0 (0)
Edema 46 4 0 0 0 0 (0)
Neuropathy: sensory 43 7 0 0 0 0 (0)
Nail changes 47 1 1 1 0 1 (2)
ALT/AST 33 14 1 2 0 2 (4)
Sodium/potassium 37 10 0 2 1 3 (6)
FIGURE 1. Progression-free survival (A) and overall survival (B) by the Kaplan–Meier method.
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(range, 1.4–19.1 months). The median progression-free sur-
vival time was 4.8 months (95% CI, 4.0–5.3) (Figure 1A).
The median survival time (MST) of all patients was 11.8
months (95% CI, 11.3–18.4), and the 1-year survival rate was
50% (Figure 1B).
Toxicity
All patients were assessed for toxicity (Table 3). Of the
24 patients who received only one or two cycles, 15 termi-
nated treatment because of their disease progression, and
three patients discontinued chemotherapy because of toxicity.
The most common hematological grade 3 or 4 adverse event
was neutropenia (38%). Febrile neutropenia was not ob-
served. Nonhematological toxicities were generally moder-
ate. Anorexia of at least grade 3 was observed in only two
patients (4%). One patient (2%) complained of grade 3 nail
changes. Grade 3 elevation of transaminase occurred in two
patients (4%). One patient developed grade 4 hyponatremia
attributable to ADH secretion abnormality, although it is
uncertain whether this had been caused by an adverse effect
of treatment or paraneoplastic syndrome. No excessive lac-
rimation was observed.
DISCUSSION
Chemotherapy with a platinum-based regimen such as
cisplatin is currently the standard regimen for advanced
NSCLC. Cisplatin, however, is toxic for many patients, who
therefore discontinue chemotherapy. The use of carboplatin
instead of cisplatin has led to improvements in toxicity, with
comparable efficacy. In advanced NSCLC, the aim of treat-
ment is not only prolongation of survival but also mainte-
nance of quality of life. Hence, it is important to develop
effective regimens with low toxicity profiles. These regimens
should also be suitable for outpatient-based chemotherapy.
In this study, we performed a phase II trial of biweekly
docetaxel combined with carboplatin for patients with ad-
vanced NSCLC. We observed an overall response rate of
30%, a 1-year survival rate of 50%, and an MST of 11.8
months. In previous phase II studies using triweekly do-
cetaxel plus carboplatin, the overall response rates were 42 to
44%, the 1-year survival rates were 53 to 53%, and the MSTs
were 12.0 to 13.9 months.8,9,16 Moreover, a recent random-
ized phase III study of docetaxel plus carboplatin showed an
overall response rate of 24%, a 1-year survival rate of 38%,
and an MST of 9.4 months.7 Thus, the efficacy and the
survival results of our biweekly regimen were comparable
with those used in earlier studies.
Interestingly, we observed a high response rate (54%)
in our elderly population, although this was only a result of
subset analysis with small sample size. Patient characteristics
such as PS or stage between younger patients and elderly
patients were not different. Monotherapy of docetaxel has
been shown to be a good option for chemotherapy in elderly
NSCLC patients, according to a recent phase III trial17; thus,
a randomized phase III study comparing our combination
regimen with docetaxel alone for the elderly patients is
warranted.
Regarding hematological toxicity, our patients experi-
enced mild adverse effects. Triweekly docetaxel plus carbo-
platin induced neutropenia in about 70% of patients and
febrile neutropenia in 3 to 15%.6–9 In contrast, we observed
grade 3 or 4 neutropenia in 38% of patients and no incidents
of febrile neutropenia, suggesting that our biweekly regimen
has a safer toxicity profile.
Nonhematological toxicities were mostly mild to moder-
ate and manageable. The incidence of grade 3 or 4 nonhemato-
logical toxic effects was rare in this study (4% anorexia, 2% nail
changes, 4% liver dysfunction, and 6% hyponatremia/hypoka-
lemia). In contrast to previous findings, we did not observe any
incidents of severe diarrhea or pulmonary toxicity.7,9,12
In conclusion, biweekly docetaxel combined with car-
boplatin had good efficacy and safety profiles compared with
the standard combination of triweekly docetaxel and carbo-
platin. Although its efficacy was not superior to that of the
standard regimen, its convenience and safety may be more
suitable for outpatients, including elderly patients or patients
with poor PS. Further trials, especially for elderly patients,
are warranted.
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